About MBX Biosciences Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://mbxbio.com/
Frequently Asked Questions
What is the 52-week range for MBX?
The 52-week high is $72.64 and the 52-week low is $12.94.
What is the P/E ratio for MBX?
The P/E ratio data is currently unavailable.
What is the dividend yield for MBX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -26.01%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.84.
Analyst Recommendation Trends
Wall Street analyst consensus for MBX over the last few months:
Latest MBX News
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences is upgraded to Buy on strong Phase 2 canvuparatide data, Phase 3 path, and cash-rich catalysts. Click for this MBX stock update.
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
MBX Biosciences, Inc. (MBX) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 8:30 AM EDTCompany ParticipantsSteven Hoerter -...
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor confer
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
CARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Jeff Held, J.D., as Chief Legal Officer. Mr. Held brings more than three decades of legal, compliance and executive leadership experience across biotechnology, l
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | -370 | $65.77 | $24,335 |
| 2026-08-03 | Smither John W | +130,000 | - | - |
| 2026-08-03 | Smither John W | +28,000 | - | - |
| 2026-08-03 | Hoerter Steven L. | +331,000 | - | - |
| 2026-08-03 | Hoerter Steven L. | +71,000 | - | - |
| 2026-06-04 | Ryder Steven | +12,500 | - | - |
| 2026-06-04 | Aynechi Tiba | +12,500 | - | - |
| 2026-06-04 | Stelzer Laurie | +12,500 | - | - |
| 2026-06-04 | Hoerter Steven L. | +12,500 | - | - |
| 2026-06-04 | Pescovitz Ora H. | +12,500 | - | - |
| 2026-06-04 | Heron Patrick J | +12,500 | - | - |
| 2026-06-04 | Mathers Edward T | +12,500 | - | - |
| 2026-05-08 | Azoulay Salomon | +15,003 | - | - |
| 2026-05-08 | Azoulay Salomon | +55,000 | - | - |
| 2026-05-08 | Azoulay Salomon | -15,003 | $38.3 | $574,615 |
| 2026-05-08 | Azoulay Salomon | +15,003 | $16 | $240,048 |
| 2026-05-08 | Azoulay Salomon | -55,000 | $38.38 | $2,110,900 |
| 2026-05-08 | Azoulay Salomon | +55,000 | $10.46 | $575,300 |
| 2026-05-06 | Azoulay Salomon | -231 | $29.54 | $6,824 |
| 2026-05-06 | Hawryluk P. Kent | -607 | $29.54 | $17,931 |
| 2026-05-01 | Hoerter Steven L. | +74,249 | - | - |
| 2026-05-01 | Hoerter Steven L. | +11,938 | - | - |
| 2026-03-13 | Hawryluk P. Kent | +18,500 | $28.4142 | $525,663 |
| 2026-02-26 | Hawryluk P. Kent | -28,768 | - | - |
| 2026-02-26 | Hawryluk P. Kent | +28,768 | $16 | $460,288 |
| 2026-02-02 | Azoulay Salomon | +70,000 | - | - |
| 2026-02-02 | Azoulay Salomon | +15,000 | - | - |
| 2026-02-02 | Bartram Richard | +70,000 | - | - |
| 2026-02-02 | Bartram Richard | +15,000 | - | - |
| 2026-02-02 | Hawryluk P. Kent | +164,500 | - | - |
| 2026-02-02 | Hawryluk P. Kent | +35,250 | - | - |
| 2026-01-20 | Stelzer Laurie | +32,000 | - | - |
| 2025-11-22 | Hoerter Steven L. | 0 | - | - |
| 2025-11-22 | Hoerter Steven L. | +8,000 | - | - |
| 2025-11-06 | Hoerter Steven L. | +33,751 | - | - |
| 2025-11-06 | Hoerter Steven L. | +100,000 | - | - |
| 2025-10-24 | Hawryluk P. Kent | -182,859 | - | - |
| 2025-10-24 | Hawryluk P. Kent | +182,859 | $3.25 | $594,292 |
| 2025-10-20 | Hawryluk P. Kent | +20,000 | $13.6395 | $272,790 |
| 2025-10-17 | Hoerter Steven L. | +20,000 | $13.2492 | $264,984 |